5-hydroxytryptophan has been researched along with Eosinophilia-Myalgia Syndrome in 7 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Eosinophilia-Myalgia Syndrome: A complex systemic syndrome with inflammatory and autoimmune components that affect the skin, fascia, muscle, nerve, blood vessels, lung, and heart. Diagnostic features generally include EOSINOPHILIA, myalgia severe enough to limit usual activities of daily living, and the absence of coexisting infectious, autoimmune or other conditions that may induce eosinophilia. Biopsy of affected tissue reveals a microangiopathy associated with diffuse inflammation involving connective tissue. (From Spitzer et al., J Rheumatol Suppl 1996 Oct;46:73-9; Blackburn WD, Semin Arthritis Rheum 1997 Jun;26(6):788-93)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether L-5-hydroxytryptophan (L-5-HTP) associated with eosinophiliamyalgia syndrome (EMS) like illness contains impurities in a fashion similar to that described in L-tryptophan associated with EMS." | 7.69 | An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. ( Casey, R; Crofford, LJ; Hallett, M; Love, LA; Massaquoi, SG; Michelson, D; Milstien, S; Page, SW; Trucksess, MW; Wilson, C, 1994) |
| "A patient suffering from endogenous depression was treated with mianserin and developed agranulocytosis." | 7.68 | [Mianserin agranulocytosis followed by oxitriptan eosinophilia]. ( García, C, 1992) |
| "A patient suffering from endogenous depression was treated with mianserin and developed agranulocytosis." | 5.28 | [Mianserin agranulocytosis followed by oxitriptan eosinophilia]. ( García, C, 1992) |
| "To determine whether L-5-hydroxytryptophan (L-5-HTP) associated with eosinophiliamyalgia syndrome (EMS) like illness contains impurities in a fashion similar to that described in L-tryptophan associated with EMS." | 3.69 | An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. ( Casey, R; Crofford, LJ; Hallett, M; Love, LA; Massaquoi, SG; Michelson, D; Milstien, S; Page, SW; Trucksess, MW; Wilson, C, 1994) |
| "A patient suffering from endogenous depression was treated with mianserin and developed agranulocytosis." | 3.68 | [Mianserin agranulocytosis followed by oxitriptan eosinophilia]. ( García, C, 1992) |
| " Extensive analyses of several sources of 5-HTP have shown no toxic contaminants similar to those associated with L-Trp, nor the presence of any other significant impurities." | 2.42 | Safety of 5-hydroxy-L-tryptophan. ( Bagchi, D; Bagchi, M; Das, YT; Preuss, HG, 2004) |
| "A patient suffering from endogenous depression was treated with mianserin and developed agranulocytosis." | 1.28 | [Mianserin agranulocytosis followed by oxitriptan eosinophilia]. ( García, C, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klarskov, K | 2 |
| Johnson, KL | 2 |
| Benson, LM | 2 |
| Cragun, JD | 1 |
| Gleich, GJ | 2 |
| Wrona, M | 1 |
| Jiang, XR | 1 |
| Dryhurst, G | 1 |
| Naylor, S | 2 |
| Das, YT | 1 |
| Bagchi, M | 1 |
| Bagchi, D | 1 |
| Preuss, HG | 1 |
| Michelson, D | 1 |
| Page, SW | 1 |
| Casey, R | 1 |
| Trucksess, MW | 1 |
| Love, LA | 1 |
| Milstien, S | 1 |
| Wilson, C | 1 |
| Massaquoi, SG | 1 |
| Crofford, LJ | 1 |
| Hallett, M | 1 |
| Sternberg, EM | 1 |
| García, C | 1 |
| Joly, P | 1 |
| Lampert, A | 1 |
| Thomine, E | 1 |
| Lauret, P | 1 |
2 reviews available for 5-hydroxytryptophan and Eosinophilia-Myalgia Syndrome
| Article | Year |
|---|---|
Safety of 5-hydroxy-L-tryptophan.
Topics: 5-Hydroxytryptophan; Adult; Animals; Antidepressive Agents; Depressive Disorder; Drug Contamination; | 2004 |
Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
Topics: 5-Hydroxytryptophan; Animals; Eosinophilia; Eosinophilia-Myalgia Syndrome; Eosinophils; Humans; Tryp | 1996 |
5 other studies available for 5-hydroxytryptophan and Eosinophilia-Myalgia Syndrome
| Article | Year |
|---|---|
Structural characterization of a case-implicated contaminant, "Peak X," in commercial preparations of 5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Chromatography, High Pressure Liquid; Drug Contamination; Eosinophilia-Myalgia | 2003 |
An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Adult; Chromatography, High Pressure Liquid; Eosinophilia; Eosinophilia-Myalgia | 1994 |
Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Chromatography, High Pressure Liquid; Dietary Supplements; Drug Contamination; | 1999 |
[Mianserin agranulocytosis followed by oxitriptan eosinophilia].
Topics: 5-Hydroxytryptophan; Agranulocytosis; Blood Cell Count; Depressive Disorder; Eosinophilia; Eosinophi | 1992 |
Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Aged; Carbidopa; Chronic Disease; Depression; Drug Therapy, Combination; Eosino | 1991 |